BriaCell Therapeutics Corp. (BCTX)
NASDAQ: BCTX · Real-Time Price · USD
0.7341
-0.0049 (-0.66%)
Aug 15, 2025, 10:46 AM - Market open

Company Description

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care.

Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.

The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.

It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer.

BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

BriaCell Therapeutics Corp.
BriaCell Therapeutics logo
CountryCanada
Founded2014
IndustryBiotechnology
SectorHealthcare
Employees16
CEOWilliam Williams

Contact Details

Address:
Bellevue Centre, Suite 300
West Vancouver, BC V7T 2X1
Canada
Phone604-921-1810
Websitebriacell.com

Stock Details

Ticker SymbolBCTX
ExchangeNASDAQ
Fiscal YearAugust - July
Reporting CurrencyUSD
CIK Code0001610820
CUSIP Number10778Y302
ISIN NumberCA1079302081
SIC Code2834

Key Executives

NamePosition
Dr. William V. Williams FCPA, M.D.Chief Executive Officer, President and Director
Gadi Levin B.Com., C.A., CPA, M.B.A.Chief Financial Officer and Corporate Secretary
Dr. Miguel A. Lopez-Lago Ph.D.Chief Scientific Officer
Dr. Giuseppe Del Priore M.D., M.P.H., MPHChief Medical Officer
Dr. Charles Louis Wiseman FACP, M.D.Founder, Principal Research Advisor and Member of Scientific Advisory Board

Latest SEC Filings

DateTypeTitle
Aug 1, 2025S-8Securities to be offered to employees in employee benefit plans
Jul 28, 2025SCHEDULE 13GFiling
Jul 22, 2025SCHEDULE 13GFiling
Jul 21, 2025SCHEDULE 13G/AFiling
Jul 16, 20258-KCurrent Report
Jul 16, 2025424B4Prospectus
Jul 15, 2025EFFECTNotice of Effectiveness
Jul 11, 2025FWPFree Writing Prospectus
Jul 10, 2025S-1/A[Amend] General form for registration of securities under the Securities Act of 1933
Jul 9, 2025S-1/A[Amend] General form for registration of securities under the Securities Act of 1933